In a large retrospective cohort study including over 1.6 million patients with Type 2 Diabetes, with no prior diagnosis of obesity associated cancers, a significantly reduced risk in 10 out of 13 obesity associated cancers was reported with the use of GLP-1 agonists, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic cancer, meningioma, and multiple myeloma 17
If youre taking or considering GLP-1 medications, understanding their potential impact on your eye health is crucial
Pharmacological activity and clinical use of PDRN
People who have been overweight or obese have the same number of L-cells as someone of a normal weight, however, our research has shown that their L-cells are totally underactive or dormant, producing little to no fullness signal
"It shouldn't just be given out like candy." "If you're starting to have vomiting and pain, and you don't seek medical care right away, it can cause death, ischemia of your intestines, which might require surgery
What was once available only to people with excellent insurance or substantial disposable income becomes accessible to a much broader population who can benefit from effective weight loss treatment
